| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | isoliquiritigenin | CTRPv2 | pan-cancer | AAC | -0.097 | 0.1 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.08 | 0.1 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |